评估 D-1553 联合 IN10018 在 KRAS G12C 突变实体瘤中的安全性和有效性的 Ib/II 期研究
一项 1b/II 期开放标签研究,旨在评估 D-1553 联合 IN10018 在患有 KRAS G12C 突变的局部晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学和疗效
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.
研究概览
详细说明
This study includes 2 phases: Phase Ib-Dose Escalation and Phase II-Dose Expansion. Phase Ib-Dose Escalation part will enroll at least 6 subjects to identify the safety and RP2D of D1553 in combination with IN10018 in KRAS G12C mutant solid tumors. Phase II-Dose Expansion part contains 3 cohorts with cohort A to enroll advanced colorectal cancer (CRC) with KRAS G12C mutation, cohort B to enroll advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, and cohort C to enroll other advanced solid tumors with KRAS G12C mutation. Phase II study is to evaluate the safety and antitumor activities of D-1553 in combination with IN10018 in KRAS G12C mutant solid tumors. The sample size in each cohort is estimated per Simon's 2-stage design. In Cohort A, when Simon's 2-stage study achieved statistical hypothesis, an open-label, randomized study will be conducted for factorial analysis to evaluate the contribution of IN10018 in the combination regimen.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
-
Bengbu、中国
- First Affiliated Hospital of Bengbu Medical College
-
Changsha、中国
- Hunan Cancer Hospital
-
Fuzhou、中国
- Fujian Cancer Hospital
-
Ganzhou、中国
- First Affiliated Hospital of Gannan Medical University
-
Nanjing、中国
- General Hospital Of Eastern Theater Command
-
Wuhan、中国
- Renmin Hospital of Wuhan University
-
Xuzhou、中国
- Xuzhou Central Hospital
-
Zhengzhou、中国
- Henan Cancer Hospital
-
Zhengzhou、中国
- The first Affiliated Hospital of Zhengzhou University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310005
- Zhejiang Cancer Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Men or women aged ≥ 18 years at the time of signing the informed consent form.
- Subjects with pathologically confirmed locally advanced or metastatic solid tumors.
- Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or DNA.
- Tumor types in different phases and cohorts: 1) Phase 1b: subjects with locally advanced or metastatic solid tumors who have progressed on or failed in standard therapy, and no standard treatment is available. 2) Phase II Cohort A: subjects with locally advanced or metastatic CRC. 3) Phase II Cohort B: subjects with locally advanced or metastatic NSCLC. 4) Phase 2 Cohort C: subjects with other locally advanced or metastatic solid tumors.
- Has measurable lesions at baseline according to RECIST 1.1 criteria.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose.
Exclusion Criteria:
- Prior KRAS G12C inhibitors treatment.
- Have known symptoms of spinal cord compression, instable or symptomatic central nervous system (CNS) metastases, and/or carcinomatous meningitis.
- Have a history of stroke or other serious cerebrovascular diseases within 12 months prior to the first dose.
- Have had interstitial lung disease or any active infection requiring systemic treatment within 14 days prior to the first dose.
- Has a history of severe cardiovascular disease such as acute myocardial infarction, severe/unstable angina, QTc prolongation, or poorly controlled hypertension.
- Haven't recovered from toxicity due to prior antitumor therapy
- Pregnant or lactating women.
- Malignant neoplasms other than study disease within 5 years prior to enrollment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1b-Dose Escalation Part
To evaluate the safety and Recommended Phase 2 dose (RP2D) of D-1553 in combination with IN10018 in previously-treated solid tumors. |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
其他名称:
|
|
实验性的:Phase II Cohort A-previously-treated CRC with KRAS G12C mutation(Treatmnt Group)
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in previously-treated CRCs with KRAS G12C mutation. |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
其他名称:
|
|
有源比较器:Phase II Cohort A-previously-treated CRC with KRAS G12C mutation (Control Group)
To evaluate the safety and antitumor efficacy of D-1553 in previously-treated CRCs with KRAS G12C mutation. |
D1553 orally taken,600mg twice a day |
|
实验性的:Phase II Cohort B-treatment-naïve or previously-treated NSCLC with KRAS G12C mutation
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in advanced NSCLCs with KRAS G12C mutation. |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
其他名称:
|
|
实验性的:Phase II Cohort C-other previously-treated solid tumors with KRAS G12C mutation
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in other solid tumors with KRAS G12C mutation |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation. |
Through study completion, approximately 3 years
|
|
Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Defined as the proportion of subjects with complete response (CR) or partial response (PR). |
Through study completion, approximately 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free Survival (PFS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Defined as the time from the first dose of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first. |
Through study completion, approximately 3 years
|
|
Duration of Response (DoR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first. |
Through study completion, approximately 3 years
|
|
Disease Control Rate (DCR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Defined as the proportion of patients with CR, PR, or stable disease (SD). |
Through study completion, approximately 3 years
|
|
Overall survival (OS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Defined as the time from the first dose of study treatment to the date of death due to any cause. |
Through study completion, approximately 3 years
|
|
Number of subjects with adverse event
大体时间:Through study completion, approximately 3 years
|
The number of subjects who experienced AEs is presented. |
Through study completion, approximately 3 years
|
|
Plasma concentrations of D-1553 and IN10018 in solid tumors with KRAS G12C mutation
大体时间:Through study completion, approximately 3 years
|
Plasma concentrations of D-1553 and IN10018 |
Through study completion, approximately 3 years
|
|
PK: Cmax of D-1553 and IN10018
大体时间:Through study completion, approximately 3 years
|
Maximum concentration (Cmax) |
Through study completion, approximately 3 years
|
|
PK: Cmin of D-1553 and IN10018
大体时间:Through study completion, approximately 3 years
|
Minimum concentration (Cmin) |
Through study completion, approximately 3 years
|
|
PK:t1/2 of D-1553 and IN10018
大体时间:Through study completion, approximately 3 years
|
Elimination half-life (t1/2). |
Through study completion, approximately 3 years
|
|
PK:CL/F of D-1553 and IN10018
大体时间:Through study completion, approximately 3 years
|
apparent clearance (CL/F) |
Through study completion, approximately 3 years
|
|
PK:Vd/F of D-1553 and IN10018
大体时间:Through study completion, approximately 3 years
|
Apparent volume of distribution (Vd/F) |
Through study completion, approximately 3 years
|
|
PK: AUC of D-1553 and IN10018
大体时间:Through study completion, approximately 3 years
|
Area under the concentration-time curve (AUC) |
Through study completion, approximately 3 years
|
合作者和调查者
调查人员
- 首席研究员:Zhengbo Song、Study Principal Investigator
出版物和有用的链接
一般刊物
- Song Z, Li X, Lin R, Shi H, Yuan Y, Liu Y, Luo Y, Lv T, Zhang Y, Zhu L, Zhu Y, Zhang L, Wang Z. Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. Lancet Respir Med. 2026 Jul 7:S2213-2600(26)00142-6. doi: 10.1016/S2213-2600(26)00142-6. Online ahead of print.
- Song Z, Zhu L, Liu Y, Lin R, Li X, Luo Y, Yuan Y, Shi H, Zhang Y, Zhang B, Zhu Y, Wang Z, Cheng X. Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. Lancet Oncol. 2026 Sep;27(9):1133-1145. doi: 10.1016/S1470-2045(26)00175-0.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- D1553-106/IN10018-602
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.